AveXis, Inc. (Nasdaq:AVXS) to Ring The Nasdaq Stock Market Opening Bell

ADVISORY, Feb. 17, 2016 --

What: 
AveXis, Inc. (Nasdaq:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will visit the Nasdaq MarketSite in Times Square in celebration of its recent initial public offering (IPO) on February 10, 2016.

In honor of the occasion, Sean P. Nolan, Chief Executive Officer will ring the Opening Bell. 

Where:
Nasdaq MarketSite – 4 Times Square – 43^rd & Broadway – Broadcast Studio

When:
Thursday, February 18, 2016 – 9:15 a.m. to 9:30 a.m. ET

AveXis Media Contact:
Lauren Barbiero
W2O Group
646-564-2156
[email protected]

Nasdaq MarketSite:
Emily Pan
(646) 441-5120
[email protected]

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: 
http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page: 
http://instagram.com/nasdaq

For news tweets, please visit our Twitter page at: 
http://twitter.com/nasdaq

For exciting viral content and ceremony photos visit our Tumblr Page: 
http://nasdaq.tumblr.com/

Webcast:
A LiveStream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.

About AveXis, Inc.
AveXis is a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company’s initial proprietary gene therapy candidate, AVXS-101, is in an ongoing Phase 1 clinical trial for the treatment of SMA Type 1.

About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.6 trillion and nearly 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

-NDAQA-